Olatec Therapeutics LLC

Olatec Industries LLC

David M Bresse

Joseph St Laurent

Gerald S Jones

Scott A Goodrich

George M Shopp

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a methanesulfonylalkylnitrile compound, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering a methanesulfonylalkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition for treating inflammation and pain

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and &#x3c9;-(methylsulfonyl)alkylamine or &#x3c9;-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering &#x3c9;-(methylsulfonyl)alkylamine or &#x3c9;-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-benzylsulfonylpropionitrile, or its pharmaceutically acceptable salts. The present invention also relates to methods of using the compound for treating inflammation or inflammatory-related disorders and pain.

Pharmaceutical use of 3-benzylsulfonylpropionitrile

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering &#x3c9;-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3-benzylsulfonylpropionitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

4-benzylsulfonyl-2-butenenitrile

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a &#x3c9;-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an &#x3c9;-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 4-methylsulfonyl-2-butenenitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred routes of administration.

4-methylsulfonyl-2-butenenitrile and its pharmaceutical use

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an &#x3c9;-(methanesulfonyl)alkenylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an &#x3c9;-(methanesulfonyl)alkenylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The present invention is further directed to a method for potentiating the analgesic effects of morphine, by administering an effective amount of 3-(methylsulfonyl)acrylonitrile to a subject who is being treated with morphine and is suffering from pain. Oral and topical administration are preferred.

Methods for treating inflammation and pain

The present invention is directed to a method of treating inflammation or pain. The present invention is also directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the disease or disorder. Topical administration and oral administration are preferred route of administration.

Pharmaceutical use of 3, 4-bis-benzylsulfonylbutyronitrile

Compounds for treating inflammation and pain

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use

The present invention relates to processes for preparing 3-methylsulfonylpropionitrile. The processes provide a good yield and a good purity of the final product and provide a controllable reaction. The present invention also relates to a crystalline form of 3-methylsulfonylpropionitrile having X-ray diffraction peaks at 13.9&#xb1;0.1, 19.2&#xb1;0.1, 20.0&#xb1;0.1, 22.5&#xb1;0.1, 23.2&#xb1;0.1, 25.7&#xb1;0.1, 28.1&#xb1;0.1, 29.9&#xb1;0.1, and 30.6&#xb1;0.1 degrees 2&#x3b8;, and wherein the most intense peak is the peak at 13.9&#xb1;0.1 degrees 2&#x3b8;.

Growing community of inventors

Middleboro, MA, United States of America

David M Bresse